5,293 Merck & Co., Inc. $MRK Shares Sold by Tectonic Advisors LLC

Tectonic Advisors LLC lessened its position in shares of Merck & Co., Inc. (NYSE:MRK) by 4.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 121,391 shares of the company’s stock after selling 5,293 shares during the period. Merck & Co., Inc. makes up 0.8% of Tectonic Advisors LLC’s portfolio, making the stock its 27th biggest position. Tectonic Advisors LLC’s holdings in Merck & Co., Inc. were worth $17,639,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Bullseye Investment Management LLC acquired a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at $27,000. Curry Webb Wealth Management LLC bought a new position in shares of Merck & Co., Inc. during the third quarter valued at approximately $29,000. Horizons Wealth Management acquired a new position in Merck & Co., Inc. during the 3rd quarter valued at approximately $30,000. Graney & King LLC grew its position in shares of Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC bought a new stake in Merck & Co., Inc. in the 2nd quarter valued at about $41,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David Williams sold 52,847 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares in the company, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock valued at $29,977,783 in the last ninety days. 0.17% of the stock is currently owned by insiders.

Merck & Co., Inc. Trading Down 1.4%

NYSE MRK traded down $1.99 on Friday, reaching $145.25. The company had a trading volume of 8,379,092 shares, compared to its average volume of 9,663,986. The stock has a market cap of $358.35 billion, a price-to-earnings ratio of 116.20, a PEG ratio of 6.83 and a beta of 0.21. The stock’s 50 day moving average is $146.98 and its 200-day moving average is $130.17. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts predict that Merck & Co., Inc. will post 2.64 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a $0.85 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. Merck & Co., Inc.’s payout ratio is currently 272.00%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 INTerpath-001 results for the personalized melanoma vaccine, intismeran, combined with Keytruda. The treatment reduced the risk of recurrence or death by 42% and also improved distant metastasis-free survival, supporting the long-term potential of the partnership’s oncology pipeline. Doctors call Moderna and Merck cancer vaccine data a major advancement
• Positive Sentiment: The European Commission approved Keytruda plus Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, regardless of patients’ cisplatin eligibility. The broader label expands the addressable market and represents the EU’s first approval of a PD-1 inhibitor combined with an antibody-drug conjugate in this setting. Merck wins EU approval for Keytruda plus Padcev
• Neutral Sentiment: Despite strong clinical results, the vaccine announcement triggered a “sell-the-news” reaction. The data largely met elevated Wall Street expectations after an earlier leak, limiting the immediate upside for MRK even though oncologists viewed the results as an important treatment advance. Merck and Moderna shares fall on cancer vaccine results
• Negative Sentiment: Investors remain concerned about valuation and Merck’s future revenue concentration in Keytruda ahead of its patent cliff. Analysts have also characterized the recent rally as leaving limited margin of safety, increasing the risk of profit-taking when news is merely in line with expectations. Merck rally leaves little margin of safety
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $2.63 from $2.73 and its FY2027 estimate to $9.38 from $9.47. Separate previews also anticipate a year-over-year decline in quarterly earnings, adding near-term pressure to the shares. Merck earnings preview

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of research analyst reports. Cantor Fitzgerald upped their price target on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. BMO Capital Markets increased their price objective on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, August 20th. Guggenheim raised their price objective on Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. Berenberg Bank raised their target price on Merck & Co., Inc. from $127.00 to $137.00 and gave the company a “hold” rating in a report on Friday, September 11th. Finally, Wells Fargo & Company upped their target price on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, September 4th. Seventeen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $151.92.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.